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The Global Initiative for Obstructive Lung Diseases (GOLD) defines COPD as a disease
that is usually progressive. GOLD also provides a spirometric classification of airflow limita-
tion. However, little is known about the long-term changes of patients in different GOLD
grades.
Objective
Explore the proportion and characteristics of COPD patients that change their spirometric
GOLD grade over long-term follow-up.
Methods
Patients alive for at least 8 years since recruitment and those who died with at least 4 years
of repeated spirometric measurements were selected from the BODE cohort database. We
purposely included the group of non survivors to avoid a “survival selection” bias. The pro-
portion of patients that had a change (improvement or worsening) in their spirometric GOLD
grading was calculated and their characteristics compared with those that remained in the
same grade.
Results
A total of 318 patients were included in the survivor and 217 in the non-survivor groups.
Nine percent of survivors and 11% of non survivors had an improvement of at least one
GOLD grade. Seventy one percent of survivors and non-survivors remained in the same
GOLD grade. Those that improved had a greater degree of airway obstruction at baseline.
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Conclusions
In this selected population of COPD patients, a high proportion of patients remained in the
same spirometric GOLD grade or improved in a long-term follow-up. These findings suggest
that once diagnosed, COPD is usually a non-progressive disease.
Introduction
The Global Initiative for Obstructive Lung Diseases (GOLD) defines chronic obstructive pul-
monary disease (COPD) as a disease "characterized by persistent airflow limitation (AL) that is
usually progressive" [1]. This implies that the forced expiratory volume in the first second
(FEV1) in most patients with COPD decreases progressively over time. The GOLD document
also grades the severity of AL and it has been assumed that most patients start in a less severe
GOLD spirometric grade of AL and progress to more severe grades as the disease worsens.
Several recent studies challenge this concept reporting that lung function progression in
COPD patients is heterogeneous, with only a minority of patients (between 20–30%) belonging
to the “rapid decliners” group [2,3,4]. These studies were based on individual longitudinal data
measured over a relatively short period of time (3–5 years) and have used the mean decline of
groups using absolute FEV1 in ml as the yardstick. Few studies have related the change of lung
function over time to disease progression. One report studied the change in GOLD spirometric
grades in a COPD population, but the changes were evaluated for only one year, too short a
time to express the progression of disease [5]. Agusti et al. [6] also explored longitudinal
GOLD grade changes in the ECLIPSE cohort during 3 years, but only for the new ABCD grad-
ing and not for the GOLD spirometric grades of AL.
Since most clinicians use the GOLD spirometric grading of airflow obstruction to determine
disease severity and progression, the present study was planned to explore the long-term
behavior of GOLD spirometric grades of AL in a large sample of well-characterized COPD
patients followed in clinics. The patients were classified into two groups: survivors (with at
least 8 years of follow-up) and, to avoid the “survivor selection” bias, non-survivors (with at
least 4 years of measurements before death).
Patients and Methods
COPD patients participating in this study were part of the BODE international cohort, pro-
spectively recruited and followed between January 1997 and December 2013 [7] in 1 hospital
in the United States (Bay Pines VAMHCS, Florida) and 3 in Spain (Hospital Miguel Servet,
Zaragoza; Clinica Universidad de Navarra, Pamplona and Hospital Nuestra Sra de La Cande-
laria, Tenerife). Regardless of disease severity, all patients regularly attending the pulmonary
clinics in those hospitals were equally invited to participate in the study. None of the patients
died while waiting to be included in the study. The detailed methodology of the BODE interna-
tional cohort recruitment and follow up protocol has been previously described [7]. Patients
were evaluated after enrolment and were seen every year or until death. The patient and family
were contacted if the patient failed to return for appointments. Death from any cause was
recorded and confirmed using death certificates in Spain, and the social security registry in the
USA.
COPD was defined by a history of smoking at least 10 pack-years and FEV1/FVC ratio less
than 0.70 after 400ug of inhaled albuterol [8]. Patients were excluded if they had a history of
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asthma, bronchiectasis, tuberculosis or other confounding diseases like severe congestive heart
failure (Stage III through IV NYHA), obliterative bronchiolitis or diffuse panbronchiolitis. All
COPD participants were clinically stable receiving standard medical treatment according to
the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines [9].
The human-research review board at each institution approved the study and all patients
signed an informed consent. (Comité de ética e investigación clínica de Aragón (CEICA), No.:
96/0115).
Clinical and physiological parameters measurements
Trained personnel obtained the following information at the time of recruitment and at each
visit thereafter: age, sex, spirometric values, mMRC dyspnea scale, six minute walk distance
(6MWD), and the body mass index (BMI), calculated as the weight in kilograms divided by
height in meters2. Patients were asked about their smoking history (age at initiation and dis-
continuation, as well as intensity), and if they still smoked (current or former) [10]. From this
information we calculated the total smoking exposure and expressed it as pack-years.
Spirometry was performed following ERS/ATS guidelines [8]. FEV1 and FVC were mea-
sured and post bronchodilator (after 400ug of inhaled albuterol) values were recorded. All
BODE sites follow strict quality control protocols of spirometry data.
For the purpose of the present study we selected patients that were alive at least for 8 years
with spirometric measurements at baseline and at year 8. We arbitrarily selected 8 years of fol-
low up for the survivors' group in an attempt to include a significant number of patients that
were followed for a long period of time (in this case 318pts). To avoid the “survivor selection”
bias, we also included a group of non survivors to determine their spirometric course. This
group included patients who had 3 or more spirometries done for 4 years before their death to
determine whether they differed in behavior from those that survived. Patients in this group
had to have the last spirometry completed within a year of the date of death.
A patient was considered to not have progressed if he/she remained in the same spirometric
GOLD grade. On the other hand, for progression there had to be a change from a lesser to a
more severe GOLD spirometric grade of AL whereas for improvement the patient had to have
changed to a lesser grade of AL. The GOLD spirometric grades used were as follows: grade I:
FEV1%>80%, II: FEV1% 50–79, III: 30–49 and IV FEV1%<30 [1].
Statistical analysis
Quantitative data with a normal distribution were expressed using the mean and the standard
deviation (SD). Quantitative data with non-normal distribution were described with the
median and the interquartile range (IQR). Qualitative data were described using relative fre-
quencies. Comparison between groups we performed using Pearson chi-square, Student t or
Mann-Whitney U according to the variables type and distribution. Bonferroni correction was
used when multiple comparisons were made.
Significant levels for all tests were established as a two-tailed p-value< 0.05. Calculations
were made with SPSS version 20.0 Inc. (IBM, Armonk, New York, USA).
Results
Fig 1 shows the flow chart of the patients included in the present study. A total of 318 COPD
patients constituted the survivor group (followed for a minimum of 8 years) and 217 formed
the non-survivor group (followed for a minimum of 4 years before they died). The clinical,
physiological and pharmacological characteristics of the patients are shown in Table 1. The
cohort consisted primarily of current and former smoking men in their 6th decade. The
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spirometric staging included patients in all stages, but with a majority in GOLD spirometric
grades II-III as is common in clinical pulmonary practice.
Fig 1. Flow chart of the patients participating in the study.
doi:10.1371/journal.pone.0151856.g001
Table 1. Baseline characteristics of all COPD patients included in this study.
Clinical and Physiological Characteristics n = 535
Patients by GOLD stages I-II-III-IV (%) 21,41,28,10
Age in years (SD) 68(9)
Gender (male%/female%) (92/8)
BMI in kg/m2 (SD) 27(5)
Pack-years (IQR) 60(40–90)
Smoking at the time of enrollment % 30












BMI: Body Mass Index; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity;
LAMA: long acting muscarinisc agents; LABA: long acting beta 2 agonists agents; ICS: inhaled
corticosteroids
doi:10.1371/journal.pone.0151856.t001
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Eighty one percent of the patients in the survivor group and 79% in the non-survivor group
remained in the same GOLD spirometric grade of AL during the observation period. Impor-
tantly, 9% of the survivors and 11% of the non-survivors actually improved their GOLD spiro-
metric grade of AL. There was no difference in the proportion of patients that either improved
or remained stable between survivors and non-survivors.
Fig 2 shows the behaviour of the COPD patients in terms of progression, non-progression
or improvement now classified by each spirometric GOLD grade. In the survivors group
(Panel A), the proportion of patients that remained unchanged was similar across GOLD spi-
rometric grades but surprisingly, a higher proportion of patients improved in the more severe
grades of obstruction. In the non-survivor group (Panel B) a high percentage of patients
remained unchanged or improved but most importantly, only a small percentage declined
before death occurred.
The clinical, physiological and pharmacological characteristics of the patients from the sur-
vivor group that did not progress, progressed and improved are shown in Table 2. Statistical
significant differences were found only in the baseline GOLD spirometric grades of AL, which
was more severe in the group that improved.
Table 3 shows the clinical, physiological and pharmacological characteristics of the patients
from the non-survivor group that did not progress, progressed and improved. No significant
statistical differences were found between groups.
Table 4 shows the cause of death by baseline GOLD spirometric grades. Patients in GOLD
spirometric grades I and II died primarily from cardiovascular disease and cancer, and those in
grades III and IV died from respiratory failure.
Discussion
There are two novel findings in this long term observational study of a large sample of COPD
patients from the BODE cohort. First, that COPD is usually a non-progressive disease with less
than 30% of the patients having a worsening of their GOLD spirometric grades of AL over at
least 4 years of follow-up. Second, approximately 10% of the patients improved their spiromet-
ric values sufficiently to have an improvement in their GOLD spirometric grades of AL. These
findings should contribute to challenge the current negative paradigm by providing a more
positive perspective of a disease usually considered to be progressive.
Traditionally, and based primarily on the epidemiological observation from Fletcher and
Peto [11], COPD has been viewed as a “usually progressive disease” [1] where patients are diag-
nosed at less severe spirometric grades and then progress over time to more severe grades. [1,
12, 13, 14]. However, this concept has been recently challenged in several studies. Sanchez-Sal-
cedo et al. [15] demonstrated that the lung function decline profile is similar in young COPD
patients and in those with older age, a finding that is not consistent with a progressive deterio-
ration of lung function over time. More evidence suggesting that lung function progression in
COPD is heterogeneous has been provided by three important studies [2, 3, 4]. Casanova et al.
[2] followed 751 patients from the BODE database for a mean time of 5 years, and found that
only 18% were “fast decliners” with a mean FEV1 decline of 86 ml/year. Similar results were
reported by Nishimura et al. [3], who analyzed a smaller sample of 261 patients also followed
for 5 years, reporting a similar proportion (25%) of “rapid decliners” who had a mean FEV1
decline of 61ml/year. Vestbo et al. [4], also reported the analysis of 2163 patients from the
ECLIPSE study followed for 3 years, and observed that at least 38% of the patients had a yearly
mean absolute FEV1 decline greater than 38ml/year. All of these studies concentrated primarily
on the factors associated with a rapid decline in lung function, even though all of them noted
the existence of a large group of patients who declined minimally and a small group that
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Fig 2. Behavior of baseline GOLD stages in each stage: Panel A for the survivors over at least 8 years of follow up and Panel B for the non survivors over at
least 4 years of follow up before death.
doi:10.1371/journal.pone.0151856.g002
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actually showed improvement in their lung function. These studies focused on the mean and
individual yearly absolute FEV1 change in ml and did not relate the magnitude of the changes
to shifts in GOLD spirometric AL grades, thereby limiting the clinical implications of the
findings.
More recently, Casanova et al. explored the CHAIN COPD Spanish cohort [5] and reported
the one year longitudinal changes of GOLD spirometric grades of AL in this population [5].
They noted that 72% of the patients remained in the same GOLD spirometric grade of AL and
13% actually improved, but the changes over that short period of time were not related to mor-
tality or other outcomes. Agusti et al. in the ECLIPSE study also explored the longitudinal
behavior of the GOLD spirometric grades of AL over 3 years but only analyzed the new ABCD
GOLD classification [6] and did not explore the relationship between those changes and
outcomes.
The present study expands on these observations exploring the long term changes in GOLD
grades in a large sample of well characterized COPD patients. It has the strength of including
patients that were followed for at least 8 years (many up to 10–12 years). The purposeful inclu-
sion of a second group of COPD patients who died after a minimum of 4 years of follow up,
was designed to minimize the potential bias of including only survivors that would have a bet-
ter course. The fact that the proportion of patients that improved the GOLD spirometric grade
of AL was similar in survivors (with a longer follow up time) and non-survivors, and that the
Table 2. Baseline characteristics of the survivor COPD patients included in this study.
Clinical and Physiological Characteristics No progression Progression Improved p value
n = 195 n = 92 n = 31 * **
Patients by GOLD stages
I-II-III-IV (%) 30,50,17,3 38,46,16,0 0,48,42,10 0.42 <0.001
Age in years (SD) 67(10) 68(9) 67(9) 0.20 0.97
Gender (male%) (95) (90) (93) 0.29 0.56
BMI in kg/m2 (SD) 27 (4) 27 (5) 28 (5) 0.68 0.87
Pack-years (IQR) 54(39–77) 60(42–84) 50(40–84) 0.27 0.53
Smoking at the time of enrollment % 34 37 29 0.51 0.68
Quitting smoking during follow up (%) 76 61 85 0.08 0.45
FEV1% (SD) 69(21) 67(20) 54(18) 0.81 <0.001
FVC% (SD) 102(19) 101(18) 92(25) 0.82 0.02
FEV1/FVC 56(10) 55(10) 51(12) 0.84 0.04
TREATMENT (%)
0.25 0.13
NONE 18 6 14
LAMA 20 19 9
LABA 2 0 5
LABA+LAMA 5 2 9
ICS+LABA 16 19 14
LAMA+LABA+ICS 39 54 45
Theophylline 0 0 4
GOLD: Global Initiative for Obstructive Lung Disease; BMI: Body Mass Index; FEV1: forced expiratory volume in the first second; FVC: forced vital
capacity; LAMA: long acting muscarinisc agents; LABA: long acting beta 2 agonists agents; ICS: inhaled corticosteroids
* Progression vs. No progression.
**Improved vs. No progression
doi:10.1371/journal.pone.0151856.t002
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proportion of patients that remained stationary (62% and 65%) was also similar in both groups,
would suggest that the improvement or stability observed is not spurious and is likely real.
The meaning of an improvement in GOLD spirometric grade has not been validated
although several studies have consistently shown that the grades themselves are very good pre-
dictors of mortality [5]. The actual reasons for this cannot be discerned in this study since it
was not planned to explore any intervention other than optimal COPD care, but it does raise
the possibility that the current standard of care is effective and provides strong support for a
positive attitude towards patients with this disease, independent of the severity of the condi-
tion. In this regard, we observed no special characteristic that helped identify patients likely to
improve over time, except for the fact that the baseline FEV1 was lower in those patients who
had the most improvement. We have no explanation for this observation, except that the pro-
portion of patients who quit smoking was higher, and the total amount of cigarettes smoked
was lower, in patients who remained stable or improved compared with those that worsened,
although it failed to reach statistical significance.
The present study has several limitations. Firstly, the findings presented are restricted to the
type of patients included in this cohort: mainly male COPD patients attending pulmonary clin-
ics. We do not know if women and/or patients attending primary care clinics will have the
Table 3. Baseline characteristics of the non-survivor COPD patients included in this study.
Clinical and Physiological Characteristics No progression Progression Improved p value
n = 129 n = 65 n = 23 * **
Patients by GOLD stages
I-II-III-IV (%) 5,24,41,30 22,38,40,0 0,32,52,16 0.67 0.46
Age in years (SD) 67(8) 71(8) 71(7) 0.03 0.04
Gender (male%) (93) (92) (92) 0.57 0.57
BMI in kg/m2 (SD) 26 (5) 26 (5) 26 (4) 0.68 0.87
Pack-years (IQR) 65(43–100) 70(50–96) 55(35–90) 0.27 0.53
Current Smoking % 25 30 13 0.23 0.15
Quitting smoking during follow up (%) 78 70 87 0.39 0.24
FEV1% SD) 43(19) 55(20) 49(17) 0.59 0.81
FVC%(SD) 84(21) 94(17) 87(23) 0.82 0.56
FEV1/FVC 47(11) 52(11) 48(13) 0.48 0.84
GOLD: Global Initiative for Obstructive Lung Disease; BMI: Body Mass Index; FEV1: forced expiratory volume in the first second; FVC: forced vital
capacity;
* Progression vs. No progression.
**Improved vs. No progression
doi:10.1371/journal.pone.0151856.t003
Table 4. Cause of death in each GOLD baseline stage category represented by % of patients.
Cause of death GOLD I GOLD II GOLD III GOLD IV
Cardiovascular disease %) 23 11 7 2
Lung Cancer %) 31 25 10 9
Other cancer %) 31 13 12 5
End stage COPD %) 8 22 55 53
Unknown %) 8 26 11 19
Infectious(pneumonia/sepsis)(%) 0 2 5 12
doi:10.1371/journal.pone.0151856.t004
COPD is a Non-Progressive Disease
PLOS ONE | DOI:10.1371/journal.pone.0151856 April 21, 2016 8 / 10
same behavior. Secondly, patients were managed differently over time as our capacity to treat
them was influenced by the advent of newer therapies. This may have influenced the rate of
FEV1 decline. However, this is true of all observational cohorts which by and large reflect real
life medicine. On the other hand, the large number of patients and the international nature of
the study decreases the chance that a systematic bias may have been applied to individual
patients according to the GOLD spirometric grading. Our data (Table 2) shows that all groups
had the same proportion of treatments regimens, suggesting that at least in this cohort treat-
ment option had little effect on spirometric GOLD grading changes. We also acknowledge that
we have no precise information on what happens in between the recorded visits and we only
present a simple bivariate analysis, with all the potential limitations this could have. Thirdly,
the BODE international cohort did not prospectively record the yearly exacerbation rate that
could have had an impact on the progression of lung function, a weakness that may limit the
strength of our findings. However, if we evaluate the results of the ECLIPSE study, where the
exacerbation rate had little effect on FEV1 decline (only 2 ± 0.5ml/year for each exacerbation)
the potential effect of this limitation is small [4]. Lastly, we should not forget the potential role
of the “size effect” on the change. We used a change of at least 1% to consider either an
improvement or a deterioration, knowing that such a small change in lung function probably
does not imply a clinically important difference. Acknowledging this important limitation, if
we would have used a higher cut off threshold to consider a change, then a much smaller per-
centage of patients would have improved or deteriorated, giving further support to the main
message of the present work that COPD is “mainly a non-progressive disease”.
In summary, the present study suggests that COPD is not markedly progressive in patients
cared for in pulmonary clinics of tertiary university care centers, since a large proportion of
patients attending clinics do not have changes, or actually improve, in their GOLD spirometric
grades of AL. This finding changes the long-term perspective of the disease from a nihilistic
one that limits the potential for improvement to a more positive one that can be used to moti-
vate patients to adopt healthier lifestyles and remain adherent to their treatment.
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